Clinical trial · Interventional
Diode Laser Treatment of Bladder Tumors
Diode Laser Treatment of Pta Low Grade Bladder Tumors in the Outpatient Department.
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Laser treatment of pTa low grade bladder tumours in the outpatient department Number of Subjects/Centres Planned: 20 patients will be included in this study. The study will be performed at Department of Urology, Bispebjerg-Frederiksberg Hospital, Copenhagen, Denmark. Primary Objective: To show that small pTa bladder tumours safely can be removed with diode laser in an outpatient department Secondary Objective: To evaluate the patients experience with the laser treatment using QOL questionaires (symptom evaluation) and Visual Analog Scale Score (pain evaluation).
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Bladder Cancer | Malignant Bladder Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Laser treatment | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- OTHER
- label
- Laser treatment
- description
- Intervention is diode laser treatment of bladder cancer through a cystoscope without sedation of the patient.
- interventionNames
- Procedure: Laser treatment
Primary outcomes (1)
- measure
- Tumour clearance
- timeFrame
- 1 month
- description
- No bladder tumor tissue in biopsies obtained from areas where a bladder tumor one month earlier has been removed by use of diode laser.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Recurrence of pTa low grade urothelial bladder tumor * Tumor \< 1.5 cm * \< 6 tumors Exclusion Criteria: * Patients with porphyria * Known hypersensitivity to Hexvix® or porphyrins * Use of any anticoagulants * Macroscopic hematuria * Pregnant or breast feeding women * Expected poor compliance * Patients \< 18 years * Patients who do not read or understand Danish
References
Publications (0)
Data not yet available